These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-000295-41 Double-blind,placebo-controlled cross-over study for evaluation of the efficacy of the PDE-5-inhibitor vardenafil on the peripheral perfusion and the clinical symptomatology of patients with Raynaud´s... not-yet-due
Not reported 2005-001596-34 Multicentre phase II trial of Bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia 2012-07-11 due-trials
Ongoing 2005-003156-35 Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study not-yet-due
Ongoing 2005-003271-21 Doppelblinde, prospektive, randomisierte, monozentrische, placebo-kontrollierte Pilotstudie zur Wirksamkeit und Sicherheit von Moxifloxacin in der Prophylaxe der Bakteriämie nach Hochdosis-Chemotherap... not-yet-due
Not reported 2005-003516-29 Prospective, randomized, double-blinded clinical trial on remifentanil for analgesia and sedation of ventilated neonates and infants 2010-04-11 due-trials
Completed, but no date 2005-004139-23 An open-label, non-randomized phase I/II trial of neoadjuvant radio-immunochemotherapy with bad-data
Not reported 2005-005393-73 A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT- PET for Early Prediction of Non-Progression in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and to A... 2010-10-18 due-trials
Completed, but no date 2005-005612-24 PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA EMMA-1 (ERBITUX FOR MULTIPLE MYELOMA) bad-data
Not reported 2006-001936-30 A phase II dose escalation study of caspofungin in patients with invasive aspergillosis 2009-10-26 due-trials
Not reported 2007-000224-41 A double-blind, multicentre, parallel group, randomised, controlled trial to evaluate the possible benefit of isoniazid dose adjustment according to the genotype for NAT2 (arylamine N-acetyltransferas... 2010-09-15 due-trials
Completed, report not yet due 2007-000233-18 Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinom 2012-06-19 not-yet-due
Not reported 2007-001573-28 Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial. 2014-10-28 due-trials
Not reported 2007-002824-13 Prospective, placebo-controlled blinded clinical trial to study the efficacy of orally administered Glucose 20% for relieving pain during nasopharyngeal suctioning in preterm infants > 1500g under CP... 2010-07-17 due-trials
Ongoing 2007-003187-22 Clinical trials for adults HD18 for advanced stages Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; treatment stratification by means of FDG-PET not-yet-due
Not reported 2007-003467-48 A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma 2013-11-17 due-trials
Ongoing 2007-004474-24 HD16 for early stages in Hodgkins Lymphoma not-yet-due
Ongoing 2007-005920-34 HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET not-yet-due
Completed, report not yet due 2007-007587-21 Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic l... 2018-01-01 not-yet-due
Ongoing 2008-000896-30 Surfactant application during spontaneous breathing with CPAP or during mechanical ventilation in the therapy of IRDS in premature infants <27 weeks not-yet-due
Not reported 2008-001421-34 Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Leuke... 2014-05-29 due-trials
Ongoing 2008-008896-32 Memory, Ageing, and the Cholinergic System not-yet-due
Ongoing 2009-010700-28 GRANITE-1 - Granulocyte-transfusions for patients with febrile neutropenia not-yet-due
Not reported 2009-012607-26 MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Advanc... 2013-12-13 due-trials
Completed, report not yet due 2009-012957-39 A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia 2015-02-12 not-yet-due
Not reported 2009-015217-52 Pilotstudie zur Pyridoxalphosphattherapie bei Patienten mit primärer Hyperoxalurie Typ I - Pilot trial on treatment of patients with primary hyperoxaluria type I with pyridoxal-phosphate 2012-09-19 due-trials
Ongoing 2010-021086-73 HD-R3i - A prospective, randomized, placebo-controlled, international, multicenter phase I/II trial of RAD001 (everolimus) in combination with DHAP as induction therapy in patients with relapsed or re... not-yet-due
Not reported 2010-022058-18 A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF CYCLOPHOSPHAMIDE AS SOLE GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-CY) 2013-11-18 due-trials
Not reported 2010-022180-35 Ofatumumab in relapsed nodular lymphocyte predominant Hodgkin Lymphoma 2015-04-22 due-trials
Not reported 2011-000911-26 Heart rate control after acute myocardial infarct 2014-02-24 due-trials
Ongoing 2011-001795-19 STATIN RECAPTURE THERAPY BEFORE CORONARY ARTERY BYPASS GRAFTING (ACRONYM: START-CABG TRIAL) not-yet-due
Completed, but no date 2011-003473-29 Trial on treatment with inhaled furosemide of preterm and term neonates with transient tachypnoea bad-data
Ongoing 2011-004593-29 Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma not-yet-due
Ongoing 2011-004698-98 A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk pateints with chr... not-yet-due
Completed, but no date 2011-005082-21 Targeted BEACOPP variants in patients with newly diagnosed advanced classical Hodgkin Lymphoma bad-data
Not reported 2011-005628-16 FTO-genotype dependent weight reduction under treatment with bromocriptin in obese patients 2015-06-03 due-trials
Other 2011-005655-13 A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922 not-yet-due
Not reported 2011-005797-32 Effentora® for Dyspnoea (EffenDys) - Fentanyl buccal tablet (FBT) for the relief of episodic dyspnoea (ED) in cancer patients: an open label, randomized, morphine-controlled, crossover, phase II trial 2014-10-29 due-trials
Not reported 2012-002887-29 Translational therapy in patients with Osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody Denosumab 2015-01-26 due-trials
Not reported 2012-003696-18 Effect of a preinterventional calorie restriction on renal function after contrast agent exposition in patients at risk. 2016-10-07 due-trials
Ongoing 2013-000577-77 EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION ACRONYM: SABATO (Staphylococcus aureus Bacteremia Antibiotic Treatment Options) not-yet-due
Completed, but no date 2013-002036-24 A non-randomised, non-comparative monocenter investigator initiated trial to assess the efficacy and safety of Carmustine in patients with BRCA1/2-associated advanced breast and ovarian cancer bad-data
Ongoing 2013-002737-38 A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations not-yet-due
Not reported 2013-003048-21 CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR) 2017-05-31 due-trials
Ongoing 2013-003211-22 A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A CLL Patients wi... not-yet-due
Ongoing 2013-003369-33 JeRiCHO (JAK-inhibition in recurrent classical Hodgkin Lymphoma): A phase II, open-label, prospective, non-randomized, multicenter clinical trial with the JAK-inhibitor ruxolitinib in patients with re... not-yet-due
Ongoing 2013-003990-89 Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin Lymphoma not-yet-due
Completed, but no date 2013-004481-34 RANDOMIZED PHASE 2 TRIAL COMPARING EXPERIMENTAL IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 S.C.,GM-CSF) IN RECURRENT HIGH RISK NEUROBLASTOMA PATIENTS WITH STANDARD IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 ... bad-data
Ongoing 2014-000569-35 A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA101 ... not-yet-due
Ongoing 2014-000580-40 A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax, GDC-0199) fo... not-yet-due
Ongoing 2014-000582-47 A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by ... not-yet-due
Ongoing 2014-000590-39 A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumu... not-yet-due
Ongoing 2014-004036-19 GHSG-AFM13 not-yet-due
Ongoing 2014-005130-55 HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD. not-yet-due
Other 2015-000568-32 Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation not-yet-due
Ongoing 2015-004936-36 A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versu... not-yet-due
Ongoing 2016-002626-37 Nivolumab and AVD in earlystage unfavorable classical Hodgkin lymphoma - A GHSG randomized, multicenter phase II trial not-yet-due
Ongoing 2016-003334-25 A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition not-yet-due